Kailera Therapeutics, Inc. (KLRA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.30B USD. 52-week range 9.76 to 28.23 USD. Data as of 2026-10-09.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor ...